Cagrilintide and Semaglutide Dosage: What the Current Research Shows

What the CagriSema dosage research actually involves

The REDEFINE trial programme is the main source of the dosage data circulating online. In REDEFINE-1, adults with obesity received a fixed combination of 2.4 mg cagrilintide and 2.4 mg semaglutide, injected subcutaneously once a week. The trial followed a gradual titration schedule, participants started at lower doses of each component and stepped up over several months before reaching the 2.4/2.4 mg maintenance pairing. Early results published in 2024 pointed to average weight reductions around 22–25% over roughly 68 weeks, figures that drew significant attention because they sit above what either medicine has achieved alone in comparable trials.

Cagrilintide is an amylin analogue: it mimics a gut hormone released after eating that signals fullness and slows the rate at which food leaves the stomach. Semaglutide, meanwhile, acts on GLP-1 receptors to reduce appetite and influence blood sugar regulation, and if you're curious about whether Wegovy increases metabolism as part of that process, that question has its own nuanced answer worth reading. The hypothesis driving the combination is that engaging two separate satiety pathways produces a greater effect than either pathway alone. That logic is plausible and the early numbers are striking, but striking trial results are not the same thing as a licensed medicine with a confirmed safety record in clinical use. The titration schedule, the exact injection technique and the side-effect profile are still being characterised across the full REDEFINE programme.

Novo Nordisk, which makes semaglutide, has filed for regulatory review in some markets, but the MHRA had not issued a UK licence for CagriSema or for cagrilintide as a standalone product as of summer 2026. Trial data cited here reflects published phase 3 interim results; the full dataset and any regulatory submission documents are the authoritative source. The licensed semaglutide dosage schedule for Wegovy is a separate, well-established pathway that is available now.

The decision you're actually making right now

If you landed here wondering whether CagriSema could be your next step, the honest answer is: not yet, not in the UK. The relevant question becomes what the best available option is for you today, and that depends on factors a prescriber needs to weigh, your BMI, any existing health conditions, what you may have tried before, and how your body has responded.

Wegovy, which contains semaglutide at the same 2.4 mg dose used in the CagriSema trials, is fully licensed and available through regulated UK pharmacies. In the STEP 1 trial, semaglutide 2.4 mg produced around 15% average weight loss over 68 weeks in adults without diabetes, as published in the New England Journal of Medicine. The MHRA went further in April 2026, approving a 7.2 mg single-dose pen that trials linked to roughly 20.7% average weight loss, narrowing the gap with trial data for the combination therapy, and the full breakdown of what that higher-strength option involves is covered on the semaglutide 5mg pen dosage page. A quick look at how the Wegovy dose schedule works gives the full picture of how titration is structured.

A common misconception worth setting aside gently: the combination therapy's higher trial numbers don't automatically make it the right choice even once it is licensed. What matters is whether a medicine is appropriate for your specific situation, tolerable at the doses involved, and part of a properly supervised plan. No dosage figure is useful in isolation from clinical context.

Why unlicensed cagrilintide is a real safety risk, not just a technicality

Some online sellers already market cagrilintide peptides, sometimes alongside semaglutide, targeting people who have read the trial results and want access ahead of licensing. The MHRA has warned consistently about this category of product. In 2025 alone, enforcement activity recovered approximately 20 million doses of illegally traded weight-loss medicines worth around £45 million, and a counterfeit manufacturing site for tirzepatide pens was raided in Northampton. The pattern is the same across these cases: buyers receive products whose contents, purity and actual dosage cannot be verified.

For a medicine pairing where titration matters (where stepping up too fast increases the likelihood of significant nausea, vomiting or worse) receiving an unverified compound with no clinical oversight is a meaningful risk, not a bureaucratic concern. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is the right place to report any suspect product or seller. Any UK pharmacy offering CagriSema for weight loss right now cannot be doing so legally; a search of the GPhC pharmacy register remains the quickest way to check whether an online pharmacy is operating within the law.

If you'd like to understand the cost context for the treatments that are available, the Wegovy pricing page sets out what private prescriptions typically involve and what a legitimate service includes.

What to do if you're ready to explore licensed options

The research around CagriSema is genuinely exciting for the field. It may well produce an important licensed medicine in the coming years. But waiting, or trying to source an unlicensed version, isn't the only path: semaglutide at its licensed doses has a decade of clinical data behind it, an established titration schedule, and a regulatory framework that protects patients. The same goes for tirzepatide (Mounjaro), which the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, showed produced greater average weight loss than semaglutide 2.4 mg in a direct comparison.

At nume, a named GPhC-registered prescriber reads every consultation personally, the same day it's submitted. There's no algorithm making the call. Our prescribers can discuss which licensed treatment fits your circumstances, whether your existing health conditions or medications are relevant, and whether the NHS route is worth exploring first. You can also read more about weight-loss treatment options generally, or browse common questions about the process. If you're ready to take that step, a free consultation with our prescribers is the right starting point, no commitment, no subscription, just a clinical conversation. Speak to our prescribers today.